Inactive Instrument

Oxford BioMedica plc Stock London S.E.

Equities

GB0006648157_GB

GB0006648157

Biotechnology & Medical Research

Sales 2023 * 90.48M 112M Sales 2024 * 130M 161M Capitalization 205M 254M
Net income 2023 * -89M -110M Net income 2024 * -38M -47.11M EV / Sales 2023 * 1.72 x
Net cash position 2023 * 49.23M 61.03M Net cash position 2024 * 15.51M 19.22M EV / Sales 2024 * 1.46 x
P/E ratio 2023 *
-2.25 x
P/E ratio 2024 *
-5.33 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.81%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 23-03-26
Director of Finance/CFO 52 17-08-28
Chairman 68 20-06-23
Members of the board TitleAgeSince
Director/Board Member 61 23-04-30
Chairman 68 20-06-23
Director/Board Member 66 16-05-31
More insiders
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. OXB Stock
  4. GB0006648157_GB Stock